Fiscal benefits of drugs a priority for cash-strapped countries

By Nick Taylor

- Last updated on GMT

Related tags: Asia pacific, Middle east

Cash-strapped countries are making biopharm consider a product’s fiscal benefits earlier in development, according to INC.

Shifts in global economics mean that countries and companies alike are facing restrictions on spending. In this economic environment biopharm must be ready to answer certain questions when seeking to commercialise a product.

Do we invest in your product if there’s no fiscal benefit compared to the incumbent product? That’s becoming more and more, unofficially, a view that many countries are taking​”, said Geoff Fatzinger, director of regulatory affairs and strategic product development at INC Research.

Fatzinger is responsible for Europe, Asia Pacific and the Middle East and fiscal considerations vary significantly across these regions. For example, emerging countries in Asia Pacific have large populations and finite resources, making them particularly keen to see return on investment.

Related products

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars